Verified developments at NIH, CDC, HHS, and FDA since the book's May 12, 2026 cutoff.
October 4, 2026
DEVELOPMENT
HHS
Michael Caputo appointed to the President's Cancer Panel
HHS announced on October 4 that President Trump has appointed Michael Caputo to the President's Cancer Panel, the independent advisory body Congress created in 1971 to monitor the National Cancer Program and report to the President on its progress. HHS's announcement describes Caputo as a communications and public-affairs veteran: HHS Assistant Secretary for Public Affairs in 2020, co-founder of a biotech firm that makes an indoor airborne virus detector, a senior campaign adviser to Trump in 2016 and 2024, and a cancer survivor. It lists no clinical or research credentials. Secretary Kennedy praised his ability to "bring people together." In September 2020 Caputo took a leave of absence from HHS after publicly disparaging federal government scientists.
Why it matters
The Cancer Panel is meant to be an independent check on the nation's cancer research and care programs, and its members have traditionally been drawn from medicine and science. This appointment fits the pattern the book documents of advisory and leadership roles at health institutions going to communicators and political allies rather than scientists. It is an appointment, not a policy change, and the panel's other members were not named in HHS's announcement.
Related: When Science Became Political, Science Under Siege
September 21, 2026
DEVELOPMENT
NIH
Preliminary
White House drafts order to put NIH grant approvals under a political commission
The Washington Post and Politico reported, and STAT followed, that President Trump directed OMB Director Russell Vought to draft an executive order creating a commission of political appointees that would have to unanimously approve NIH research grants, reportedly with NIH Director Jay Bhattacharya among its members. The plan followed a contentious White House meeting on September 18. Senate Appropriations Chair Susan Collins (R-Maine) and Sen. Patty Murray (D-Wash.) publicly opposed it. As of September 23, no order had been signed.
Why it matters
If signed, this would be the most direct political control over federal research funding documented since the book's May 2026 cutoff, continuing its account of the NIH grant terminations.
Related: When Science Became Political, Science Under Siege
September 18, 2026
DEVELOPMENT
CDC
CDC's measles count passes 3,880 and lists two deaths; Pennsylvania alone has reported four
As of October 1, CDC lists 3,887 confirmed U.S. measles cases in 2026 (up from 3,471 on September 17 and 2,289 in all of 2025), with 42 new outbreaks this year and about 95% of cases outbreak-associated. CDC's page now shows two measles deaths, a figure it says is "subject to change," while Pennsylvania has reported four measles-associated deaths in about a month, including an unvaccinated 18-year-old. CDC says deaths must be confirmed through the National Center for Health Statistics and that it is working with the Council of State and Territorial Epidemiologists on a standard case definition for measles deaths. Pennsylvania had conditioned its request for CDC outbreak assistance (Epi-Aid) on the deaths being counted; an HHS spokesperson called that “political blackmail,” and House Energy and Commerce Democrats requested a CDC briefing by September 28. Updated October 7.
Why it matters
The question is whether the nation's disease-surveillance agency is accurately reporting its own outbreak — the institutional-trust issue the book documents.
Related: When Science Became Political
September 18, 2026
EVIDENCE UPDATE
FDA
Nearly 600 FDA-required postmarket safety studies are behind schedule
A KFF Health News analysis of FDA databases found nearly 600 postmarket studies running behind schedule, covering about 350 drugs, biologics, and devices; more than 250 had final reports due before July 31, 2026. Examples include Amgen's Tavneos, whose required safety study had enrolled 21 of 300 planned patients before FDA moved to withdraw approval over liver injuries, and Sarepta's Exondys 51, whose confirmatory study is nearly a decade overdue. HHS said a delay alone is not evidence of an unresolved safety problem.
Why it matters
Accelerated approval assumes the evidence arrives after a product reaches the market. This analysis shows how often it doesn't.
Related: Before the Counter, Prescription Drugs research guide
September 17, 2026
DEVELOPMENT
CDC
Updated COVID vaccines stall for the half of U.S. children who rely on Vaccines for Children
Three weeks after FDA approved updated COVID-19 vaccines in late August, CDC had not opened ordering through the Vaccines for Children program, which covers roughly half of U.S. children. Adding a vaccine to the program requires a vote by CDC's Advisory Committee on Immunization Practices, which has not met since March 2026, when a federal judge blocked HHS's vaccine-schedule overhaul and ruled that Secretary Kennedy's replacement of committee members violated federal procedures. HHS said officials were “finalizing decisions.”
Why it matters
Parents may never see the advisory-committee fight, but they see the result: the children most dependent on public programs can't get a vaccine available to everyone else.
Related: When Science Became Political
September 17, 2026
DEVELOPMENT
HHS
Kennedy appoints eight members to the U.S. Preventive Services Task Force
After months of vacancies, HHS named eight new members to the task force whose recommendations determine which preventive services insurers must cover at no cost, with pediatric hematologist-oncologist Seth Corey as chair. STAT noted the picks lean toward medical specialists rather than the front-line primary-care clinicians the panel has traditionally drawn on. The eight join eight sitting members.
Why it matters
The Supreme Court's 2025 Kennedy v. Braidwood decision upheld the Secretary's authority over this panel. This is the first time that authority has been used to reshape it.
Related: When Science Became Political
September 16, 2026
DEVELOPMENT
NIH
Researchers file class action alleging NIH screened grants against a list of 235 banned terms
Researchers from the University of Pittsburgh, Stanford, and Penn State, represented by the ACLU and Protect Democracy, filed a proposed class action alleging NIH screened grant applications against 235 keywords — including “equity,” “gender,” “climate change,” and “pregnant individual” — and then terminated existing grants, denied new ones, or required researchers to strip the flagged language. The suit claims violations of the First Amendment and of federal law requiring merit-based review.
Why it matters
It is the first legal challenge aimed at the screening process itself rather than at individual grant terminations.
Related: When Science Became Political, Science Under Siege
September 8, 2026
DEVELOPMENT
FDA
HHS names four permanent FDA leaders, including agency's first AI-focused deputy commissioner
HHS announced four senior FDA leadership selections on September 8, 2026: Jared Seehafer as the agency's first Deputy Commissioner for Technology and Artificial Intelligence, Michael Davis as Director of the Center for Drug Evaluation and Research (CDER), Karim Mikhail as Director of the Center for Biologics Evaluation and Research (CBER) - the division that oversees vaccines - and Bret Koplow as Director of the Center for Tobacco Products (CTP). Secretary Kennedy said the appointees “will drive the reforms needed to confront our nation's most serious health challenges”; Acting Commissioner Kyle Diamantas framed the selections as building “the workforce needed to accelerate innovation across all FDA centers.”
Why it matters
CBER is the division whose vaccine-review authority the book's Chapter 8 tracks through Peter Marks's 2025 resignation and the leadership churn that followed; a permanent director there - alongside a newly created AI-focused deputy commissioner role - is the clearest signal yet of how this FDA intends to run, filled in ahead of (not after) Heidi Overton's still-unconfirmed nomination to the top job.
Related: When Science Became Political, Science Under Siege
September 4, 2026
EVIDENCE UPDATE
CDC
U.S. measles cases reach 3,134 for 2026 — highest total in 35 years, first possible deaths under CDC review
CDC's updated count puts 2026 measles cases at 3,134 (3,118 across 47 U.S. jurisdictions, plus 16 among international visitors) as of September 4 — up from the 2,371 cases confirmed through July 31, and the highest annual total since the 1989-91 resurgence that produced more than 55,000 infections and 123 deaths. About 94% of cases involve unvaccinated people or those with unknown vaccination status. Pennsylvania reported two measles-associated deaths on August 25 - the first potential U.S. measles deaths of 2026 - which CDC has not yet confirmed measles caused or contributed to.
Why it matters
The book's core arithmetic - measles needs 95% MMR coverage to stop moving, and coverage has fallen below it - has now produced not just a worse case count than all of 2025, but potentially this year's first deaths, still under CDC review. NIH Director Bhattacharya called the outbreak the worst in 35 years and urged vaccination in an August 9 television interview; the case count has grown by more than 700 in the five weeks since.
Related: When Science Became Political
August 29, 2026
EVIDENCE UPDATE
HHS
The Project 2025 Connection: testing the blueprint against what happened at CDC, NIH, and HHS
Project 2025's Mandate for Leadership proposed narrowing CDC's policy authority, breaking what it called the “NIH monopoly on directing research,” and restructuring HHS. A new page compares that written blueprint, published before the administration took office, against the documented institutional changes at CDC, NIH, and HHS since February 2025 — the 2,400 CDC terminations, the 2,291 NIH grant cancellations, the HHS reorganization from roughly 82,000 to 62,000 employees, and the ACIP dismissal — point by point.
Why it matters
The book already documents each of these changes on its own terms. What's new is a documented external blueprint to test them against, which is a different and higher standard of evidence than pattern-matching after the fact. The page is explicit about what this does and doesn't prove: correspondence, not causation.
Related: The Project 2025 Connection, When Science Became Political
August 24, 2026
DEVELOPMENT
HHS
Preliminary
HHS requests public comment on overhauling federal vaccine recommendation categories
Following an August 10, 2026 executive order on childhood vaccine recommendations, HHS published a formal Request for Information asking whether the current framework of routine, risk-based, and shared clinical decision-making vaccine categories should change — including whether a new “recommended, but not during infancy” category should be created. The RFI is tied to the reinstated Task Force on Safer Childhood Vaccines and takes public comment through September 20, 2026.
Why it matters
This does not change any vaccine recommendation by itself — the notice explicitly says so. But it's a documented first step toward restructuring how the federal government decides which vaccines are universally recommended versus individually decided, directly continuing the ACIP-authority story the book documents through the June 2025 committee dismissal.
Related: When Science Became Political, Science Under Siege
August 19, 2026
DEVELOPMENT
FDA
Preliminary
Trump nominates Heidi Overton, White House domestic policy aide, as FDA Commissioner
President Trump nominated Heidi Overton — deputy director of domestic policy at the White House, who has worked closely with HHS Secretary Robert F. Kennedy Jr. and Dr. Oz on health initiatives — to lead the FDA. The nomination follows a stretch of turnover in FDA vaccine leadership that the book documents through Peter Marks's 2025 resignation. Coverage describes her as untested on independent FDA oversight, with observers flagging "competing interests" between administration priorities and the agency's traditional role. At her Sept. 24 Senate HELP hearing, Overton said she would "follow the law" if the White House pressed her to change vaccine policy, called the MMR vaccine safe and effective, and declined to "prejudge" the FDA's ongoing review of the abortion pill mifepristone. She would not say whether she would resist the President if asked to do something she opposed. No committee vote has been scheduled; the committee is split 12 Republicans to 11 Democrats.
Why it matters
The book's Chapter 8 tracks the FDA's vaccine-division churn — two commissioners and two vaccine-division directors in fourteen months. A nominee who came up through White House domestic policy rather than the agency or independent science continues that pattern rather than breaking it. The Sept. 24 hearing produced assurances to follow the law but no commitment of independence from the White House. This is still a nomination, not a confirmation — the Senate has not voted.
Related: When Science Became Political, Science Under Siege
August 5, 2026
DEVELOPMENT
CDC
Senate confirms Erica Schwartz as CDC Director, ending nearly year-long vacancy
The Senate confirmed Dr. Erica Schwartz, a retired rear admiral in the U.S. Public Health Service Commissioned Corps who helped run COVID-19 testing sites in the first Trump administration, as CDC director by a 51-44 vote. She fills a vacancy that followed her predecessor's removal after a 29-day tenure — the gap the book's Chapter 6 documents as "The Valentine's Day Massacre and After." At her confirmation hearing, Sen. Bill Cassidy pressed her on how she'd resist political pressure from Secretary Kennedy; she gave little detail but told CDC staff she is prepared to "speak truth to power."
Why it matters
This is the book's central open storyline resolving in real time: does the CDC get a director able to act independently, or another one who doesn't survive contact with the agency's political environment? She now has to navigate an active measles outbreak, a foodborne parasite outbreak, and Ebola in Africa — with the vaccine-schedule fight already set by her predecessor's absence.
Related: When Science Became Political, Science Under Siege
August 5, 2026
POLICY CHANGE
HHS
HHS decertifies Kentucky-region organ procurement organization over patient safety failures
HHS decertified Network for Hope, the organ procurement organization serving Kentucky, Indiana, Ohio, and West Virginia, after federal investigators found serious deficiencies in nearly 30% of reviewed cases — including donation procedures continuing on patients showing signs they weren't suitable donors. The case traces to TJ Hoover, a Kentucky man who survived an organ-retrieval attempt in 2021 after opening his eyes and grabbing at doctors' hands during the procedure. The organization is appealing and says it has since implemented a mandatory "pause in procedure" process, now written into Kentucky law.
Why it matters
Not a vaccine story, but the same institution and the same secretary — a data point on how this HHS leadership uses its enforcement authority when the politics aren't polarized. Worth including precisely because it's a case where the agency acted on a documented patient-safety failure rather than a contested scientific claim.
Related: When Science Became Political
July 15, 2026
EVIDENCE UPDATE
NIH
Survey: 93% of cancer-disparities researchers report disruption from NIH funding cuts
A 122-researcher survey by the American Association for Cancer Research found 93% reported federal policy changes affected their work, 78% were unable to apply for funding they'd otherwise have sought, and 59% had ongoing projects disrupted. The underlying cuts — including 181 National Cancer Institute grants worth over $317 million in the first half of 2025 — predate this survey; what's new is the first systematic measurement of the damage, including stopped clinical trials where enrolled patients lost access to treatment mid-study.
Why it matters
The book's Chapter 7 puts a dollar figure on NIH's 2025 grant terminations — $2.45 billion, 2,291 grants. This survey is the first evidence of what that number actually did to the people running the underlying research, not just the institutions receiving the money. It's exactly the kind of "what do we know now that we didn't before" update the site's evidence-update category exists for.
Related: When Science Became Political